← Back

Shanghai Sanyou Medical Co Ltd

Shanghai Sanyou Medical Co., Ltd. researches, develops, manufactures, and sells orthopedics implants in China. It is also involved in production of ultrasonic power equipment and consumables. The company offers spinal and trauma implants under Tytus and Sanyou brand. Its spinal products comprise anterior cervical plate, anterior thoracolumbar, posterior cervical, posterior thoracolumbar, and minimally invasive products; and shoulder and elbow system, hip and pelvis system, knee joint system, foot and ankle, and palm and wrist systems. In addition, the company offers spinal implant, trauma implant consumables, ultrasonic power system products, and vertebral body shaping consumables. Further, it provides sports medicine and surgical equipment. Shanghai Sanyou Medical Co., Ltd. was founded in 2005 and is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 688085.CG
688085.CG

Sanyou Medical's 2026 interim net profit was 27.752 million yuan, down 24.18% year-on-year

Sanyou Medical released its 2026 interim report, with net profit attributable to the parent company of 27.752 million yuan, a decrease of 24.18% compared with the same period last year. The company's total operating revenue was 274 million yuan, and net cash inflow from operating activities was 8.0359 million yuan. The latest asset-liability ratio was 9.69%, gross margin was 75.00%, ROE was 1.30%, and diluted earnings per share was 0.08 yuan.
Jiemian·2dRead more ▾
688085.CG

Sanyou Medical's first-half net profit attributable to parent was 27.75 million yuan, down 24.2% year-on-year

Sanyou Medical released its 2026 interim report. Operating revenue was 274 million yuan, up 9.7% year-on-year. Net profit attributable to the parent was 27.75 million yuan, down 24.2% year-on-year. Net profit attributable to the parent after deducting non-recurring items was 14.25 million yuan, down 45.2% year-on-year. Second-quarter operating revenue was 150 million yuan, up 12.8% year-on-year, and net profit attributable to the parent was 20.7 million yuan, down 13.0% year-on-year. The company said that after excluding share-based payment expenses, asset and credit impairment losses, and foreign exchange losses, net profit attributable to the parent achieved substantial growth. It also invested in Zhuiyuan Medical to strengthen its layout in the cell therapy field.
财中社·3dRead more ▾
688085.CG

Sanyou Medical plans to buy back shares worth 90 million to 180 million yuan for equity incentives

Sanyou Medical announced that its board of directors has approved a share buyback plan through centralized bidding. The company intends to use its own funds and a special stock buyback loan to repurchase shares at a price not exceeding 18.90 yuan per share, with a total buyback amount of no less than 90 million yuan and no more than 180 million yuan. The buyback period is within six months from the date of board approval. Based on the maximum buyback price, the estimated number of shares to be repurchased ranges from 4.7619 million to 9.5238 million shares, accounting for 1.30 percent to 2.60 percent of the company's total share capital. The repurchased shares will be used for equity incentives or employee stock ownership plans. If not fully utilized within three years, the remaining unused repurchased shares will be cancelled. The company has obtained a loan commitment letter from the Jiading sub-branch of Shanghai Pudong Development Bank, promising to provide a special loan for the stock buyback.
中国证券报·31dRead more ▾
Robotics & Physical AI3

Sanyou Medical completes installation of first multi-arm spinal surgery robot in Europe

Sanyou Medical announced that its subsidiary, France-based Implanet, in collaboration with the Amiens-Picardie University Medical Center, has completed the installation of the first Chunfenghuayu 8i Robotics multi-arm humanoid intelligent spinal surgery robot in Europe. The collaboration aims to conduct clinical evaluation research and EU CE certification for the world's first multi-arm humanoid intelligent surgical robot in the field of spinal surgery. Following installation, a series of scientific research and clinical work targeting spinal surgery and neurosurgery will be initiated to validate the performance of its core technologies—including electromagnetic navigation, integrated digital microscopy, and multi-arm coordination combined with Shuimu Tianpeng ultrasonic bone scalpel technology—in complex real-world clinical environments. Currently, the Chunfenghuayu 8i Robotics multi-arm humanoid intelligent surgical robot has completed research and clinical installations at five hospitals across North America, Asia, and Europe.
证券时报·41dRead more ▾
688085.CG

Multiple Listed Companies Disclose Buyback and Shareholding Increase Plans, Signaling Long-Term Confidence

On the evening of July 14, several listed companies including Yuanwanggu, Yahua Electronics, and Sanyou Medical disclosed buyback plans, while Seres, Haitian Precision, and Jack Technology announced shareholding increases by controlling shareholders or senior executives. Yuanwanggu plans to repurchase shares worth 50 million to 100 million yuan for equity incentives or employee stock ownership plans, having just implemented a 2025 cash dividend of 10.0015 million yuan. Directors, senior executives, and key team members of Seres plan to increase their holdings of A-shares and H-shares by a total of no less than 119 million yuan and no more than 154 million yuan, following an earlier shareholding increase plan announced by the controlling shareholder Xiaokang Holdings. Haitian Precision's controlling shareholder Haitian Co. increased its holdings by 1.3388 million shares on the same day, with an amount of 24.6658 million yuan, and plans to continue increasing holdings by a total of 25 million to 50 million yuan within six months. Market participants believe that listed companies are taking concrete actions to reshape market expectations, and regulatory authorities are continuously improving institutional arrangements to promote the use of buyback and shareholding increase tools.
证券时报·44dRead more ▾